| Similar Articles |
|---|
 |
The Motley Fool
September 14, 2007
Brian Orelli |
Good News About Propecia and Cancer Recent studies show that Merck's hair-loss remedy doesn't cause cancer. Instead, it helps doctors find tumors. Does this present another revenue stream for the drug as a cancer preventative?   |
AskMen.com
Jacob Franek |
Prostate Cancer Treatment And Prevention Everything you wanted to know about prostate cancer in our three-part Prostate Cancer Guide. |
American Family Physician
May 15, 2005 |
Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options. |
AskMen.com
Jacob Franek |
Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide. |
AskMen.com
Jen Woodward |
Prostate Cancer 101 Here are some of the basic facts about prostate cancer, along with what you can do to keep the C-word from gracing your medical chart. |
The Motley Fool
December 2, 2010
Brian Orelli |
An Ounce of Prevention Gets Shot Down An FDA panel shoots down Merck's and Glaxo's prostate drugs. |
AskMen.com
Alex Santoso |
Prostate Health 101 Most men don't have any clue about their prostate -- until things go wrong. With this information, they can maximize their prostate health. |
AskMen.com
Jacob Franek |
Prostate Cancer Symptoms, Screening & Diagnosis Despite the facts that prostate cancer is the No. 1 cancer occurring in men (aside from skin cancers) and the second leading cause of cancer death (behind lung cancer), many men are still unfamiliar with this highly treatable disease. |
BusinessWeek
February 16, 2004
Catherine Arnst |
Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs. |
AskMen.com
Jacob Franek |
4 Fun Ways To Help Prevent Prostate Cancer We're not pretending that there's anything fun about prostate cancer. We are attempting to encourage men to take measures to prevent the disease. |
Chemistry World
February 11, 2009
Lewis Brindley |
Prostate Cancer Biomarker Could Speed Diagnosis US researchers have identified a compound in urine that could be used to detect prostate cancer - and also to distinguish between benign and invasive forms of the disease. |
Nutra Solutions
July 1, 2005 |
Soy Claims Count Regular consumption of soy protein-containing foods and beverages may reduce the risk of breast cancer in women by as much as 22%, reports a study published in The International Journal of Cancer Prevention. |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
| AskMen.com |
Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good. |
The Motley Fool
September 28, 2010
Brian Orelli |
Pfizer's Sutent Fails. Again! No surprise here. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
Nurse Practitioner
October 2009
Wallace et al. |
Shedding light on prostate cancer This article will discuss the risk factors, signs and symptoms, diagnosis of prostate cancer, and disease staging and grading, as well as necessary lab and diagnostic tests, treatment options and patient education. |
BusinessWeek
February 6, 2006
Gene G. Marcial |
If Clinical Trials Pan Out, GTx Could Have A Winner Tiny Biotech GTx is a high-risk stock since it depends on a new drug's outcome. |
The Motley Fool
June 9, 2010
Denise Gellene |
Gen-Probe Prostate Cancer Test Looks Promising The new test could eliminate need for painful biopsies. |
The Motley Fool
March 14, 2006
Brian Gorman |
AstraZeneca's Heartening News A new study shows cholesterol drug Crestor's further potential. Will it help sales? |
The Motley Fool
December 23, 2009
Brian Orelli |
Cancer Isn't Merck's Biggest Problem There's still hope for Merck's Vytorin, but investors will have to wait. |
AskMen.com
March 17, 2001
Joshua Levine |
The Importance Of Regular Check-Ups For Men Men are much less likely than women to seek the routine medical care that they should. This article describes some of the risks. |
Managed Care
April 2004
Jack McCain |
Statin Therapy: More Than Meets the Eye? Statin selection has just become more complicated. Will physicians be diverted from interventions that may be less costly and just as effective? |
Chemistry World
September 28, 2012
Andrew Turley |
Regorafenib approved in US US authorities have approved Stivarga (regorafenib) tablets for the treatment of advanced colorectal cancer. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
BusinessWeek
July 3, 2006
Catherine Arnst |
A Ton Of Prevention The pros and cons of two drugs that may halve your risk of breast cancer. |
BusinessWeek
July 21, 2003
Amy Barrett |
A Bare-Knuckle Battle over Cholesterol Drugs If AstraZeneca's Crestor is approved, rivals' stepped-up pitches will focus on safety |
AskMen.com
Jacob Franek |
Testicular Cancer Myths While sometimes deciphering the truth is not simple, we dispel five of the most common myths surrounding testicular cancer. |
The Motley Fool
December 14, 2010
Brian Orelli |
An Ounce of Prevention, a Pound of Blockbuster Sales Amgen's Xgeva recently gained Food and Drug Administration approval to treat cancer patients that have bone metastasis. |
Salon.com
April 28, 2000
Dawn MacKeen |
A disease fueled by testosterone When a politician announces he has prostate cancer, what does it mean? |
BusinessWeek
May 12, 2011
Robert Langreth |
Big Pharma Bets on a Novel Cancer Cure Research in epigenetics is booming. The payoff could be in the billions. |
BusinessWeek
June 6, 2005
Catherine Arnst |
Better Odds Against Breast Cancer New treatments for breast cancer are more effective, and easier to live with |
The Motley Fool
August 2, 2004
Brian Gorman |
Will Lipitor's Certification Boost Pfizer? The FDA's ruling may help the company ward off a new threat. |
AskMen.com
April 15, 2014
Naomi Mead |
Don't Put Your Sexual Health At Risk! Eat These 5 Foods Right Now & Protect Yourself. It is believed that a high-sugar, high-fat, processed Western diet may have a significant part to play in the increased rates of prostate cancer we are now observing. |
American Family Physician
August 15, 2000
Sharon Scott Morey |
AUA Issues a Policy Report on PSA Monitoring The American Urological Association (AUA) has released a policy report on the use of prostate-specific antigen (PSA) in screening for and monitoring of prostate cancer. |
Science News
May 19, 2007 |
Science Safari: Cancer Risk -- Understanding the Puzzle This new Web site from the National Cancer Institute cuts through the hype to help you understand the plain and simple truth about cancer risk. |
The Motley Fool
September 27, 2011
Brian Orelli |
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. |
AskMen.com
Jen Woodward |
Health Exams 101 A list of the most important medical exams men should be undergoing on a regular basis. |
Managed Care
June 2001 |
New Cholesterol Guidelines Could Mean Higher Premiums A jump in sales of cholesterol-reducing drugs could accompany the National Cholesterol Education Program's new practice guidelines on management of hypercholesterolemia -- an expense that health plans are likely to pass on to subscribers... |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
November 15, 2011
Brian Orelli |
Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck. |
The Motley Fool
September 2, 2008
Brian Orelli |
Cardiologists Hate Vytorin Cardiologists seem cynical about the full presentation of Merck's and Schering-Plough's SEAS data at the European Society of Cardiology. |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
AskMen.com
November 23, 2003
Martin Selby |
Medical Checkups: What To Examine Although many men tend to avoid doctors like the plague, here are some health issues you might want a doctor to check out. |
HHMI Bulletin
Nov 2010 |
Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers. |
Salon.com
July 14, 2000
Arthur Allen |
The cancer study bombshell that wasn't Were the New York Times and the Washington Post writing about the same New England Journal of Medicine article? |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
